Published in Blood Weekly, July 28th, 2005
Ceflatonin is currently in a phase II clinical trial at the M.D. Anderson Cancer Center in Houston, Texas treating chronic myeloid leukemia (CML) patients who are resistant to Gleevec. In addition to CML, Ceflatonin has established clinical activity in other hematological malignancies (blood cell cancers) including myelodysplastic syndrome and acute myeloid leukemia.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.